Behçet's disease

From Wikipedia, the free encyclopedia

You have new messages (last change).
Behçet's disease
Classifications and external resources
ICD-10 M35.2
ICD-9 136.1
OMIM 109650
DiseasesDB 1285
eMedicine med/218  ped/219 derm/49 oph/425

Behçet's disease, is a chronic condition due to disturbances in the body’s immune system. This system, which normally protects the body against infections through controlled inflammation, becomes overactive and produces unpredictable outbreaks of exaggerated inflammation. This extra inflammation affects blood vessels, usually the small ones. As a result, symptoms occur wherever there is a patch of inflammation, and can be anywhere where there is a blood supply.

Contents

[edit] Synonyms

Behçet's syndrome, Morbus Behçet, silk road disease.

[edit] History

Behçet's disease is named after Hulusi Behçet (1889-1948), the Turkish dermatologist and scientist who first recognized the syndrome in one of his patients in 1924 and reported his research on the disease in Journal of Skin and Veneral Diseases in 1936. The name (Morbus Behçet) was formally adopted at the International Congress of Dermatology in Geneva in September 1947.

The disease was probably first described by Hippocrates in the 5th century BC, in his 3rd Epidemion-book. [1]

[edit] Pronunciation note

Because it contains a cedilla, "Behçet" is frequently wrongly assumed to be French in origin and pronounced with a sibilant "s" sound (as in "satsuma") or soft "ch" (as in "shoe"), with the "t" incorrectly silenced: "Beshay". Because Hulusi Behçet was Turkish, the correct pronunciation is with a hard "ch", as in "choice", and with the terminal "t" sounded: "Beh-chet".

[edit] Pathology

The symptoms of Behçet's disease are believed to be caused by an over-active immune system which, without any apparent infections, produces recurrent outbreaks of inflammation in small blood vessels. Common symptoms include mouth ulcers, sore genitals and eye inflammation, and arthritis in older patients, mostly painful but not life-threatening conditions. However, some patients may be unable to work because of the pain and the impaired vision and mobility. In some severe cases, uncontrolled inflammation may lead to blindness, intestinal complications, stroke, and even meningitis, which can be fatal.

This disease usually first strikes patients in their 20s and 30s. It then becomes a fluctuating lifelong disorder with a series of remissions and exacerbations which can be from days to months. Complete remission is rare.

[edit] Diagnosis

There is no specific pathological test for Behçet's disease at present. It is diagnosed clinically by specific patterns of symptoms and repeated outbreaks. Other causes for these symptoms have to be ruled out before making the diagnosis. The symptoms do not have to occur together, but can have happened at any time.

There are three levels of certainty for diagnosis:

  1. International Study Group diagnostic guidelines (very strict for research purposes)
  2. Practical clinical diagnosis (generally agreed pattern but not so strict)
  3. 'Suspected' or 'Possible' diagnosis (incomplete pattern of symptoms)

[edit] International Study Group diagnostic guidelines

Must have

  • mouth ulcers (any shape, size or number at least 3 times in any 12 months),

along with 2 out of the next 4 "hallmark" symptoms:

  • genital ulcers (including anal ulcers and spots in the genital region and swollen testicles or epididymitis in men),
  • skin lesions (papulo-pustules, folliculitis, erythema nodosum, acne in post-adolescents not on corticosteroids),
  • eye inflammation (iritis, uveitis, retinal vasculitis, cells in the vitreous),
  • pathergy reaction (papule >2 mm dia. 24-48 hrs or more after needle-prick).

[edit] Practical clinical diagnosis

Must have

along with 1 of the 4 hallmark symptoms above and with 2 of the symptoms below:

[edit] 'Suspected' or 'Possible' diagnosis

Usually given when someone does not have mouth ulcers or has mouth ulcers but does not have 1 of the 4 hallmark symptoms but has other symptoms and signs of inflammation and other causes for these have been ruled out.

[edit] Causes

No one knows why the immune system starts to behave this way in Behcet’s disease. It is not because of any known infections, it is not hereditary, it does not have to do with ethnic origin, gender, life-style, or age, where someone has lived or where they have been on holiday. It is not associated with cancer, and links with tissue-types (which are under investigation) are not certain. It does not follow the usual pattern for autoimmune diseases.

[edit] Treatment

Current treatment is aimed at easing the symptoms, reducing inflammation, and controlling the immune system. Anti-TNF therapy such as infliximab has shown promise in treating the uveitis associated with the disease (Sfikakis et al, 2001; Sfikakis, 2002). Another Anti-TNF agent, Etanercept, may be useful in patients with mainly skin and mucosal symptoms (Melikoglu, 2005).

Interferon alfa-2a may also be an effective alternative treatment, particularly for the genital and oral ulcers (Alpsoy, 2002) as well as ocular lesions (Kotter, 2003). Azathioprine, when used in combination with interferon alfa-2b also shows promise (Hamuryudan, 2002), and Colchicine can be useful for treating some genital ulcers, erythema nodosum, and arthritis in women, and arthritis in men (Yurdakul et al, 2001).

Thalidomide has also been used due to its immune-modifying effect (Hamuryudan et al, 1998). Dapsone and rebamipide have been shown, in small studies, to have beneficial results for mucocutaneous lesions (Matsuda et al, 2003;Sharquie et al, 2002).

[edit] Epidemiology

Behçet's disease is considered more prevalent in the areas surrounding the old silk trading routes in the Middle East and in Central Asia. Thus, it is sometimes known as Silk Road Disease. However, this disease is not restricted to people from these regions.

An estimated 15,000 to 20,000 Americans have been diagnosed with this disease. In the UK, it is estimated to have about 2 cases for every 100,000 people.

Globally, males are affected more frequently than females. In the United States, more females are affected than males.

[edit] References

  • Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E (2002). "Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study". Arch Dermatol 138 (4): 467-71. PMID 11939808.
  • Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H (1998). "Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial". Ann Intern Med 128 (6): 443-50. PMID 9499327.
  • Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H (2002). "Interferon alfa combined with azathioprine for the uveitis of Behcet's disease: an open study". Isr Med Assoc J 4 (11 Suppl): 928-30. PMID 12455182.
  • Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stubiger N (2003). "Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis". Br J Ophthalmol 87 (4): 423-31. PMID 12642304.
  • Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y (2003). "Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study". Drugs R D 4 (1): 19-28. PMID 12568631.
  • Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan V, Yazici H (2005). "Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study". J Rheumatol 32 (1): 98-105. PMID 15630733.
  • Sfikakis PP (2002). "Behcet's disease: a new target for anti-tumour necrosis factor treatment". Ann Rheum Dis 61 Suppl 2: ii51-3. PMID 12379622.
  • Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001). "Effect of infliximab on sight-threatening panuveitis in Behcet's disease". Lancet 358 (9278): 295-6. PMID 11498218.
  • Sharquie KE, Najim RA, Abu-Raghif AR (2002). "Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study". J Dermatol 29 (5): 267-79. PMID 12081158.
  • Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H (2001). "A double-blind trial of colchicine in Behcet's syndrome". Arthritis Rheum 44 (11): 2686-92. PMID 11710724.

[edit] External links

Retrieved from "http://en.wikipedia.org../../../b/e/h/Beh%C3%A7et%27s_disease.html"